FY ended March 2026
- Overall sales increased 4.3% over the previous fiscal year. In Japan, the Company concentrated on enhancing sales activities which match each market; the acute care hospital market, the small and mid-sized hospital market, and the clinic market. The Company also focused on its consumables and services business as well as strengthening its marketing and service capabilities, creating customer value which contributed to improving medical safety, patient outcomes, and operating efficiency. Domestic sales decreased due to restraining sales of locally purchased products and lower sales of Abbott products. Internationally, sales achieved double-digit growth, because sales in all regions increased favorably. Overseas sales also increased favorably on a comparable basis excluding the currency effect and the impact of the consolidation of Ad-Tech.
- Operating income decreased 9.5%, as domestic sales decreased and SG&A expenses increased due to wage increases and R&D investments as well as higher depreciation caused by M&A and capital investments.
- Ordinary income increased 10.7%, reflecting foreign exchange gains compared to losses in FY2024.
- Income attributable to owners of parent increased 2.9%, as extra payments for early retirements were recorded as extraordinary losses.
| 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|
| Net Sales(million yen) | 205,129 | 206,603 | 221,986 | 225,424 | 235,099 |
| Operating Income(million yen) | 30,992 | 21,120 | 19,591 | 20,713 | 18,745 |
| Ordinary Income(million yen) | 34,563 | 24,122 | 25,589 | 20,373 | 22,544 |
| Income Attributable to Owners of Parent(million yen) | 23,435 | 17,110 | 17,026 | 14,098 | 14,513 |
| Net Income per Share (EPS) *1 (yen) | 276.51 | 203.28 | 101.23 | 84.88 | 89.25 |
| Total Assets(million yen) | 210,201 | 216,728 | 233,233 | 258,276 | 256,538 |
| Net Assets(million yen) | 156,381 | 167,604 | 181,082 | 181,294 | 179,824 |
| Equity Ratio(%) | 74.4 | 77.3 | 77.6 | 69.5 | 70.1 |
| Return on Equity (ROE)(%) | 15.9 | 10.6 | 9.8 | 7.8 | 8.1 |
| Return on Assets (ROA)(%) | 17.1 | 11.3 | 11.4 | 8.3 | 8.8 |
|
- Effective July 1, 2024, each share of common stock was split into two shares. Net income per share is calculated on the assumption that the stock split was implemented at the beginning of FY ended March 31, 2024.
- Number of Employees at the end of each fiscal year.
Caution
-
These data are prepared based on the financial results reports.
-
The frequency of updates may change in accordance with changes to the format of the financial results reports.
-
Please see the financial results reports and other materials for detailed information regarding the settlement of accounts.
-
The contents of these data will not immediately reflect corrections to the financial results reports when announced.
-
While we pay due caution to the conversion of data for the posting, please note that there is a possibility that errors may occur in the information due to uncontrollable circumstances, such as the unauthorized alteration of contents by a third party or mechanical defects resulting from equipment malfunction.
-
Service provided by Nomura Investor Relations Co., Ltd.
Powered by ShareWith
